FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]
Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Mar 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 4970523013 | Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 4970524019 | Alogliptin (as alogliptin benzoate) 25 mg and pioglitazone (as pioglitazone hydrochloride) 45 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Alogliptin and pioglitazone only product in oral dose form | true | Inferred relationship | Some | ||
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Pioglitazone hydrochloride | true | Inferred relationship | Some | 1 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Pioglitazone (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Alogliptin benzoate (substance) | true | Inferred relationship | Some | 2 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Alogliptin | true | Inferred relationship | Some | 2 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets